Crispr Therapeutics AG enters its Q3 2026 report with a consensus revenue estimate of $16.56 million and an expected EPS of -$1.06, while the stock currently trades at $51.72 against a median analyst target of $80.00.
Investors are primarily focused on the commercial execution of Casgevy, the world’s first approved CRISPR-based therapy, as the market looks for evidence of a sustained ramp in patient treatment initiations.
The quarter is pivotal following recent label expansions in the U.S. and U.K. for children as young as two years old, which significantly widened the therapy's addressable market. Additionally, analysts are monitoring the cardiovascular pipeline, particularly CTX310, as the company seeks to demonstrate clinical progress beyond its core hemoglobinopathy franchise.